CN1101846A - Chinese medicine of anticoagulating and lowering blood fat for cardiovascular and cerebrovascular diseases - Google Patents
Chinese medicine of anticoagulating and lowering blood fat for cardiovascular and cerebrovascular diseases Download PDFInfo
- Publication number
- CN1101846A CN1101846A CN 93118572 CN93118572A CN1101846A CN 1101846 A CN1101846 A CN 1101846A CN 93118572 CN93118572 CN 93118572 CN 93118572 A CN93118572 A CN 93118572A CN 1101846 A CN1101846 A CN 1101846A
- Authority
- CN
- China
- Prior art keywords
- treatment
- cardiovascular
- blood fat
- chinese medicine
- cerebrovascular diseases
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The Chinese medicine for cardiovasular and cerebrovascular diseases can lower blood viscosity and prevent and cure thrombosis. Its total effective rate is 85.7% for lowering serum triglyceride and 68.2% for lowering serum chloesterol. It is also suitable for fatty liver, renal arteriosclerosis, etc..
Description
For the purpose of making things convenient for the patient, during clinic trial, once replaced title of the present invention with simple code name " blood fat reducing I number ".This code name and title of the present invention have equivalent meanings.
The invention relates to cardiovascular and cerebrovascular disease internal medicine, Chinese medicine and Chinese materia medica.
In recent years, coronary heart disease, myocardial infarction and by it cardiovascular disease such as arrhythmia that cause, and various cerebrovascular disease such as cerebral arteriosclerosis, cerebral ischemia, cerebral hemorrhage, cerebral thrombosis, also have fatty liver, renal arteriosclerosis or the like, more and more seriously threatening people's life and health.Developing of these serious diseases all deposits in blood vessel wall and other internal organs with lipid, and forms atherosclerosis, and it is relevant to produce the consequence of hemorheology change etc.And the existing Therapeutic Method of these diseases, again biasing toward taken stopgap measures more, and relatively, the therapy of effecting a permanent cure is then relatively weaker.Obviously,, and remove their threat, must fundamentally be conceived to improve intravital lipid metabolism situation if think more effectively to treat these diseases.Once the someone estimated, if can make serum cholesterol content reduce by 25%, and then the mortality rate of coronary heart disease just can reduce by 50%.
In addition, along with the raising of people's living standard and the change of dietary structure, and the development trend of social age structure aging, make the sickness rate of hyperlipemia to present obvious ascendant trend in recent years.Not only in the patient that hospital seeks medical advice, even in the health check-up of normal population, especially in the crowd more than 45 years old, hyperlipemia has become common phenomenon.These people are huge reserve crowds that possible develop into the severe cardiac cerebrovascular disease.According to the principle of " putting prevention first ", early treatment's Primary hyperlipemia, the therapy of effecting a permanent cure with above-mentioned severe cardiac cerebrovascular disease has meaning of equal importance.
At present, the existing cardiovascular and cerebrovascular disease medicine that can improve lipid metabolism, mostly be simple fat-reducing medicament, and the overwhelming majority is Western medicine (as: clofibrate derivant, HMG-CoA reductase inhibitor, resinae, probacol, nicotinic acid, Pantosin, an Acipimox etc.), they or need rely on external import, and price is expensive partially; Part perhaps still has some deficits at curative effect, side effect aspects such as (comprising the anti-phenomenon that jumps of treatment).About Chinese traditional treatment, though kind of a Chinese herbal medicine has effect for reducing fat surplus having confirmed 60, the curative effect of folk prescription treatment is limited; And compound treatment is controlled and aspect such as Chinese and Western combination all has bigger difficulty in dialectical opinion, needs the long term experience accumulation, thereby has also limited the curative effect that compatibility is used.Therefore, above medicine all can not satisfy the clinical demand of cardiovascular and cerebrovascular diseases far away, and places hope on new drug or new prescription.
The objective of the invention is,, by improving lipid metabolism, thereby improve hemorheological property and blood fat reducing, reach the effect of treatment and prevention cardiovascular and cerebrovascular disease at last from the angle of effecting a permanent cure.Its indication scope comprises, coronary heart disease and by cardiovascular disease such as it arrhythmia that causes, myocardial infarctions, and cerebrovascular disease such as cerebral arteriosclerosis, cerebral ischemia, cerebral thrombosis also have fatty liver, renal arteriosclerosis etc.Simultaneously, also be applicable to simple Primary hyperlipemia, promptly simple serum cholesterol (TC) or serum triglycerides (TG) content increase.
Chinese medicine preparation provided by the invention is:
Pollen Typhae 6-30g Semen Coicis 10-30g Fructus Crataegi 10-30g
Rhizoma Alismatis 10-30g Semen Cassiae 10-30g
The result of the present invention's research summary that is the inventor on clinical practice basis for many years.After the prescription typing, go through (1990-1992) more than 2 years 110 routine patients' clinical trial treatment and observation again.
Accept the patient of clinical trial and observation,, cut out all Chinese medicines and medicines such as blood fat reducing Western medicine and aspirin from test the last fortnight.Before two weekends of what drug withdrawal and on-test, get venous blood mensuration serum cholesterol (TC), serum triglycerides (TG) and hemorheological indexes on an empty stomach, simultaneously, also check indexs such as liver function, fasting glucose, hematuria routine.MethodsThe cases enrolled must or serum TC＞200mg%, perhaps TG＞160mg%, perhaps two indexs all raise.Then, the beginning medicine of the present invention the treatment that is decocted in water for oral dose, every day potion, every dose of branch is taken for 2 times, eight weeks were a course of treatment.During the treatment, keep normal diet.The course of treatment, above-mentioned same index was measured in check when finishing.
Experimental observation is the result show, 110 example treatments all obtain good curative effect.Below enumerate 30 examples and take the medicine patient of the present invention detail statistics data of (being called the treatment group), in the hope of curative effect, side effect etc. is more strictly analyzed summary.In addition, outside above-mentioned 110 examples, select 20 cases else as matched group, so that comparative analysis.Matched group replaces taking outside the medicine of the present invention divided by taking Pantosin, and other various conditions and disposal are all identical with the treatment group.
1. the efficient statistical data of blood fat reducing
Efficient evaluation, " the blood fat efficacy assessment standard " that adopts Shanghai City coronary heart disease cooperative groups to draft, promptly TC, the TG value after the treatment reduced to normally, the 20% above person that perhaps descends is a produce effects, decline 10-20% is effective, decline 10% with next be invalid.
By the effective percentage of table 1 treatment group as seen, medicine of the present invention is all effective to reducing serum cholesterol (TC) and reducing serum triglycerides (TG), and the effect of reduction serum triglycerides (TG) is more remarkable, and total effective rate is up to 85.7%; The total effective rate that reduces serum cholesterol (TC) is 68.2%.In addition, the curative effect of treatment group is higher than matched group, and two groups of differences that reduce serum triglycerides (TG) total effective rate have statistical significance.
The effective percentage of table 1. blood fat reducing treatment
The total routine number * produce effects example of index group is the invalid routine total effective rate % of example effectively
Treatment organizes 22 11 47 68.2
TC matched group 16 42 10 37.5
The p value〉0.05
Treatment organizes 28 18 64 85.7
TC matched group 19 52 12 36.8
P value＜0.01
* remove the case that TC or TG individual event do not exceed normal range.
2.TC and the statistical data of TG average
Table 2 shows that all than obviously descending before the treatment, particularly the decline of serum triglycerides (TG) is particularly evident for serum cholesterol (TC) after the treatment of treatment group and serum triglycerides (TG) average.The decline of treatment group simultaneously, is more obvious than matched group again.Treatment, the average difference of contrast between two groups are not had statistical significance before treatment, then present statistical significance after treatment, and this shows the difference of curative effect between two groups, the influence that not selected by case, but due to the medicine difference.
The treatment influence of table 2. couple TC, TG average (standard deviation)
(mg%) treatment back (mg%) p value before the treatment of index group example number
Treatment organizes 30 223.74 (41.75) 196.43 (37.74)＜0.001
TC matched group 20 234.67 (48.85) 224.62 (42.08)〉0.05
The p value〉0.05＜0.05
Treatment organizes 30 230.39 (75.74) 169.20 (68.17)＜0.001
TC matched group 20 236.53 (56.39) 243.25 (96.20)〉0.05
The p value〉0.05＜0.01
3. about the statistical data of hemorheology property improvement
Table 3 is the statistical result that six hemorheology indexs of treatment group are measured, and the every index after the treatment all demonstrates the significance with statistical significance and changes.Determine that from the variation of these hemorheology indexs medicine of the present invention has the tangible blood viscosity that improves, and therefore prevent and treat the effect of thrombosis.This is the not available characteristic of fat-reducing medicament generally commonly used.
The treatment influence of table 3. pair hemorheology index average (standard deviation)
Treatment back p value before the index treatment
Whole blood viscosity (height is cut) (mPa.s) 6.78 (1.28) 6.45 (1.24)＜0.001
Whole blood viscosity (low cut) (mPa.s) 11.11 (3.53) 9.64 (2.99)＜0.001
Plasma viscosity (mPa.s) 1.85 (0.15) 1.63 (0.18)＜0.001
Packed cell volume (%) 47.10 (4.29) 44.70 (4.40)＜0.001
Erythrocyte aggregation index 1.66 (0.24) 1.42 (0.18)＜0.001
Erythrocyte electrophoretic time (S) 19.31 (2.49) 17.01 (2.71)＜0.001
4. an inspection such as the liver function before and after the treatment, blood glucose, hematuria routine, all no change.Any toxic and side effects and the anti-phenomenon that jumps of treatment are not found in clinical observation yet.
Above-mentioned every statistical data fully shows, the present invention can not have under the situation of toxic and side effects, the clear and definite lipid metabolism that improves effectively, thereby improve hemorheological property and improve blood viscosity, the while blood fat reducing, therefore, can play the effect of treatment and prevention cardiovascular and cerebrovascular disease from the angle of effecting a permanent cure.Comparative analysis also shows, its blood fat reducing curative effect height simultaneously, can obviously improve hemorheological property again, and this is two outstanding features of the present invention.
At last, the present invention have also that the flavor number of prescription is few, the medicine source side just, advantage such as cost is low, preparation is easy, the patient is easy to accept and can popularize.
Claims (1)
- The cardiovascular and cerebrovascular diseases Chinese medicine preparation of anticoagulating and lowering blood fat is:Pollen Typhae 6-30g Semen Coicis 10-30g Fructus Crataegi 10-30gRhizoma Alismatis 10-30g Semen Cassiae 10-30g
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 93118572 CN1101846A (en) | 1993-10-20 | 1993-10-20 | Chinese medicine of anticoagulating and lowering blood fat for cardiovascular and cerebrovascular diseases |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 93118572 CN1101846A (en) | 1993-10-20 | 1993-10-20 | Chinese medicine of anticoagulating and lowering blood fat for cardiovascular and cerebrovascular diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1101846A true CN1101846A (en) | 1995-04-26 |
Family
ID=4992539
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 93118572 Pending CN1101846A (en) | 1993-10-20 | 1993-10-20 | Chinese medicine of anticoagulating and lowering blood fat for cardiovascular and cerebrovascular diseases |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1101846A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1079253C (en) * | 1998-12-24 | 2002-02-20 | 赵徕淋 | Medicinal oil for dredging channels and collaterals of heart and brain and its preparing process |
| WO2006081739A1 (en) * | 2005-02-06 | 2006-08-10 | Xinfu Guo | A composition for treating or preventing hyperlipemia, hypertension and hepatic adipose infiltration |
| CN104547779A (en) * | 2015-02-09 | 2015-04-29 | 王士国 | Lipid lowering and meridian unblocking medicament for treating chronic arteriosclerosis and preparation method of medicament |
| CN104758836A (en) * | 2015-04-08 | 2015-07-08 | 江苏碧云天农林科技有限公司 | Lipid-lowering traditional Chinese medicinal composition containing semiaquilegia adoxoides |
| CN105308158A (en) * | 2013-02-25 | 2016-02-03 | 福斯特惠勒（美国）公司 | Increased production of fuels by integration of vacuum distillation with solvent deasphalting |
| CN114767801A (en) * | 2022-05-10 | 2022-07-22 | 北京中医药大学东方医院 | Traditional Chinese medicine composition for preventing and treating atherosclerosis cerebral infarction |
-
1993
- 1993-10-20 CN CN 93118572 patent/CN1101846A/en active Pending
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1079253C (en) * | 1998-12-24 | 2002-02-20 | 赵徕淋 | Medicinal oil for dredging channels and collaterals of heart and brain and its preparing process |
| WO2006081739A1 (en) * | 2005-02-06 | 2006-08-10 | Xinfu Guo | A composition for treating or preventing hyperlipemia, hypertension and hepatic adipose infiltration |
| CN105308158A (en) * | 2013-02-25 | 2016-02-03 | 福斯特惠勒（美国）公司 | Increased production of fuels by integration of vacuum distillation with solvent deasphalting |
| CN104547779A (en) * | 2015-02-09 | 2015-04-29 | 王士国 | Lipid lowering and meridian unblocking medicament for treating chronic arteriosclerosis and preparation method of medicament |
| CN104758836A (en) * | 2015-04-08 | 2015-07-08 | 江苏碧云天农林科技有限公司 | Lipid-lowering traditional Chinese medicinal composition containing semiaquilegia adoxoides |
| CN104758836B (en) * | 2015-04-08 | 2017-12-15 | 江苏碧云天农林科技有限公司 | A kind of Chinese medicinal composition for reducing blood fat containing Gynura bicolor |
| CN114767801A (en) * | 2022-05-10 | 2022-07-22 | 北京中医药大学东方医院 | Traditional Chinese medicine composition for preventing and treating atherosclerosis cerebral infarction |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Gudmand-Høyer et al. | Prophylactic effect of cimetidine in duodenal ulcer disease. | |
| Kaplan | Behavior as the central outcome in health care. | |
| Kudolo | The effect of 3‐month ingestion of Ginkgo biloba extract (EGb 761) on pancreatic β‐cell function in response to glucose loading in individuals with non‐insulin‐dependent diabetes mellitus | |
| Tornvall et al. | A comparison between nicotinic acid and acipimox in hypertriglyceridaemia—effects on serum lipids, lipoproteins, glucose tolerance and tolerability | |
| CN1101846A (en) | Chinese medicine of anticoagulating and lowering blood fat for cardiovascular and cerebrovascular diseases | |
| Golding et al. | Observations on the treatment of rheumatoid disease with penicillamine | |
| CN101879272B (en) | Chinese medicinal compound for treating coronary heart diseases, preparation method and application thereof | |
| CN1262284C (en) | Health care product of hippophae rhamnoides oil | |
| Gundersen et al. | Halofantrine-associated ventricular fibrillation in a young woman with no predisposing QTc prolongation | |
| CN1207044C (en) | Antilipemic antiatherosclerosis medicine composition and preparing method, application thereof | |
| Lithell et al. | Effects of small doses of bisoprolol on blood pressure and lipoprotein concentrations in hypertensive patients | |
| Samvelovna et al. | INFLUENCE OF ANTIHYPERTENSIVE DRUGS ON INSULIN RESISTANCE AND LIPID SPECTRUM INDICATORS | |
| Sweeney et al. | Efficacy and compliance with cholestyramine bar versus powder in the treatment of hyperlipidemia | |
| CN101837104A (en) | Fat optimizing capsules | |
| TWI698244B (en) | Use of a combination of small-molecule fucoidan and fucoxanthin for preparing a composition for improving non-alcoholic fatty liver | |
| Hameed et al. | Antidiabetic Drugs Influences of the Activity of Acetylcholinesterase in Type 2 Diabetic Mellitus | |
| Srivastava et al. | Effect of Oxyjun™ on Adipose Tissue Inflammation-A Randomized, Placebo-Controlled Clinical Study | |
| Mitsuma | Preventive effects of eastern medication (Kampo) on the progression of chronic renal failure | |
| Momen et al. | Effect of Ramadan fasting on blood glucose and serum lipid profiles in Libyan diabetic patients | |
| Derosa et al. | Olea Europaea Effects on Glyco-Metabolic Parameters and on Glycemic Status in Patients with Impaired Fasting Glucose | |
| Shinkawa et al. | Adverse effects during endocrine therapy for prostatic carcinoma with a high dose of estrogen | |
| Jasim et al. | LIPID PROFILE IN NON-DIALYSIS AND HEMODIALYSIS CHRONIC RENAL FAILURE PATIENTS IN KIRKUK CITY | |
| Osamah | Atypical Guillain--Barre syndrome with T6 sensory level | |
| Kuang et al. | EFFECTS OF HIGH-DOSE VS. ROUTINE-DOSE CONTINUOUS HEMODIAFILTRATION ON TREATMENT OUTCOMES IN PLAYERS WITH SEVERE PANCREATITIS | |
| Meneguelli | Effect of cashew nut (Anacardium occidentale L.) and its by-products (oil and soluble extract) on biomarkers of cardiometabolic risk and gut health |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C01 | Deemed withdrawal of patent application (patent law 1993) | ||
| WD01 | Invention patent application deemed withdrawn after publication |